Fig. 1: RBD-CLP vaccine design and characterization. | Nature Communications

Fig. 1: RBD-CLP vaccine design and characterization.

From: Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Fig. 1: RBD-CLP vaccine design and characterization.The alternative text for this image may have been generated using AI.

a Schematic representation of the complete SARS-CoV-2 spike protein including the two RBD-Catcher antigen designs. NTD = N-terminal domain, FL = full-length, RBD = receptor-binding domain, SD1 = subdomain 1, SD2 = subdomain 2, FP = fusion peptide, HR1 = heptad repeat 1, HR2 = heptad repeat 2, TM = transmembrane region, IC = intracellular domain. b Individual vaccine components on a reduced SDS-PAGE. M: marker, lane 1: unconjugated Tag-CLPs (16.5 kDa), lane 2: RBDc-CLP conjugation after overnight incubation at 4 °C (60 kDa), lane 3: RBDc-CLP conjugation after overnight incubation at 4 °C (60 kDa) + spin test, lane 4: unconjugated Tag-CLPs (16.5 kDa), lane 5: RBDn-CLP conjugation after overnight incubation at RT (60 kDa), lane 6: RBDn-CLP conjugation after overnight incubation at RT (60 kDa) + spin test. This test was repeated >5 times and showed consistent results. c Schematic representation of the Tag/Catcher-AP205 technology used to create the RBD-CLP vaccines. The genetically fused peptide Tag at the N-terminus of each AP205 capsid protein (total of 180 subunits per CLP) allows unidirectional and high-density coupling of the RBD antigens, via interaction with the N- or C-terminal Catcher (i.e. the corresponding binding partner). d Structural illustration of the RBD-CLP vaccines, based on the SARS-CoV-2 spike (Sequence ID: QIA20044.1), Tag/Catcher, and AP205 CLP (Sequence ID: NP_085472.1)41 structures. The Tag is shown in red, Catcher in green, RBD in grey with the amino acids residues involved in ACE2 binding interface shown as red spheres.

Back to article page